AR121692A1 - Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas - Google Patents

Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas

Info

Publication number
AR121692A1
AR121692A1 ARP210100788A ARP210100788A AR121692A1 AR 121692 A1 AR121692 A1 AR 121692A1 AR P210100788 A ARP210100788 A AR P210100788A AR P210100788 A ARP210100788 A AR P210100788A AR 121692 A1 AR121692 A1 AR 121692A1
Authority
AR
Argentina
Prior art keywords
binding
antigen
molecule
multispecific antigen
gpc3
Prior art date
Application number
ARP210100788A
Other languages
English (en)
Spanish (es)
Inventor
Sotaro Naoi
Shu Feng
Siok Wan Gan
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR121692A1 publication Critical patent/AR121692A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ARP210100788A 2020-03-31 2021-03-30 Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas AR121692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020062357 2020-03-31

Publications (1)

Publication Number Publication Date
AR121692A1 true AR121692A1 (es) 2022-06-29

Family

ID=77928944

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100788A AR121692A1 (es) 2020-03-31 2021-03-30 Moléculas de unión a antígeno multiespecíficas activadoras de la inmunidad y usos de estas

Country Status (9)

Country Link
US (1) US20230147840A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126958A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021175391A (cg-RX-API-DMAC7.html)
KR (1) KR20220161156A (cg-RX-API-DMAC7.html)
CN (1) CN115315447A (cg-RX-API-DMAC7.html)
AR (1) AR121692A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105566TA (cg-RX-API-DMAC7.html)
TW (1) TW202204410A (cg-RX-API-DMAC7.html)
WO (1) WO2021200896A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
CA2929044A1 (en) 2013-11-11 2015-05-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified antibody variable region
US11154615B2 (en) 2014-11-11 2021-10-26 Chugai Seiyaku Kabushiki Kaisha Library of antigen-binding molecules including modified antibody variable region
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
WO2019232523A1 (en) * 2018-06-01 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
US20250051443A1 (en) * 2021-10-07 2025-02-13 National Research Council Of Canada Anti-cd3 monoclonal antibodies and therapeutic constructs
US20250000976A1 (en) * 2021-10-07 2025-01-02 National Research Council Of Canada Anti-bcma single domain antibodies and therapeutic constructs
US20250376509A1 (en) * 2023-11-21 2025-12-11 Janssen Biotech, Inc. Methods for treatment of myeloproliferative neoplasms
WO2025210181A1 (en) * 2024-04-04 2025-10-09 Cdr-Life Ag Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
WO2025226541A2 (en) * 2024-04-26 2025-10-30 Janssen Biotech, Inc. Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer
WO2026086936A1 (en) * 2024-10-24 2026-04-30 Itabmed Co., Ltd. Uses of multispecific antigen binding proteins capable of binding cd19 and cd3
WO2026136923A1 (en) * 2024-12-20 2026-06-25 Vir Biotechnology, Inc. Therapeutic uses of her-2 targeted bispecific polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
JP7357616B2 (ja) * 2017-12-05 2023-10-06 中外製薬株式会社 Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子
JP2022501325A (ja) * 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
KR20210068079A (ko) * 2018-09-28 2021-06-08 추가이 세이야쿠 가부시키가이샤 Cd3 및 cd137에 결합할 수 있지만 동시에는 결합하지 않는 항원 결합 분자

Also Published As

Publication number Publication date
WO2021200896A1 (en) 2021-10-07
JP2021175391A (ja) 2021-11-04
CN115315447A (zh) 2022-11-08
TW202204410A (zh) 2022-02-01
US20230147840A1 (en) 2023-05-11
EP4126958A4 (en) 2024-07-24
SG11202105566TA (en) 2021-11-29
EP4126958A1 (en) 2023-02-08
KR20220161156A (ko) 2022-12-06

Similar Documents

Publication Publication Date Title
de Jong et al. A CRISPR-Cas9-based reporter system for single-cell detection of extracellular vesicle-mediated functional transfer of RNA
Qin et al. ER-mitochondria contacts promote mtDNA nucleoids active transportation via mitochondrial dynamic tubulation
Miao et al. Glucose dissociates DDX21 dimers to regulate mRNA splicing and tissue differentiation
MX2021003608A (es) Moleculas de union a antigeno capaces de unirse al cumulo de diferenciacion 3 (cd3) y al cumulo de diferenciacion 137 (cd137) pero no simultaneamente.
Zhang et al. Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor
Venter et al. A triple co-culture method to investigate the effect of macrophages and fibroblasts on myoblast proliferation and migration
JOP20230246A1 (ar) أجسام مضادة لـ cd122 واستخداماتها
AR069776A1 (es) Anticuerpos bivalentes biespecificos
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
CL2022002625A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
Wang et al. Inhibition of LDHA deliver potential anticancer performance in renal cell carcinoma
BR112022021426A2 (pt) Anticorpo biespecífico anti-cd73/anti-pd-1, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para preparar o anticorpo biespecífico anti-cd73/anti-pd-1, conjugado, kit, usos do anticorpo biespecífico anti-cd73/anti-pd-1, composição farmacêutica, método in vitro, linhagem celular de hibridoma e anticorpo monoclonal anti-cd73
Vinken et al. Trichostatin a enhances gap junctional intercellular communication in primary cultures of adult rat hepatocytes
Li et al. MicroRNA-214 targets COX-2 to antagonize indoxyl sulfate (IS)-induced endothelial cell apoptosis
Dippong et al. Hapten-specific single-cell selection of hybridoma clones by fluorescence-activated cell sorting for the generation of monoclonal antibodies
Lee et al. Effect of cations in ionic liquids on the extraction characteristics of 1, 3-propanediol by ionic liquid-based aqueous biphasic systems
Loy et al. ByeTAC: Bypassing E‑Ligase-Targeting Chimeras for Direct Proteasome Degradation
Nagata et al. Focal segmental glomerulosclerosis; why does it occur segmentally?
Ito et al. Single-chain tandem macrocyclic peptides as a scaffold for growth factor and cytokine mimetics
CL2025001727A1 (es) Moléculas de unión de antígenos que se unen a partículas de aav y usos
Yang et al. Constructing GFP-based reporter to study back splicing and translation of circular RNA
Morelle et al. Cubilin and amnionless protein are novel target antigens in anti–brush border antibody disease
Parmar et al. Assessment of the therapeutic benefit of dexamethasone cyclophosphamide pulse versus only oral cyclophosphamide in phase II of the dexamethasone cyclophosphamide pulse therapy: a preliminary prospective randomized controlled study
BR112022014333A2 (pt) Anticorpos multiespecíficos para uso no tratamento de doenças
Yamanashi et al. Chemical catalyst manipulating cancer epigenome and transcription

Legal Events

Date Code Title Description
FB Suspension of granting procedure